Anastasia Ushtanit

Ms. Anastasia Ushtanit

Laboratory of molecular diagnostic technology, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
AUAnastasia Ushtanit
Anastasia Ushtanit
EKElena Kulagina
Elena Kulagina
YMYulia Mikhailova
Yulia Mikhailova
MMMarina Makarova
Marina Makarova
SSSvetlana Safonova
Svetlana Safonova
Danila ZimenkovDanila Zimenkov
Danila Zimenkov
Background: Ethionamide and prothionamide are now included in group C of the WHO recommended drugs for the treatment of tuberculosis resistant to rifampicin and multidrug-resistant tuberculosis. The clinical relevance of ethionamide and prothionamide has increased with the wide spread of resistant tuberculosis. Methods: We retrospectively analyzed 349 clinical isolates obtained between 2016 and 2020. The susceptibility to ethionamide was tested using both the BactecTM MGITTM 960 system and the SensititreTM MYCOTB plate. Results: The MIC of ethionamide increases with the total resistance of the isolates in a row from susceptible to XDR strains. A significant part of the isolates have a MIC below the breakpoint: 25%, 36%, and 50% for XDR, pre-XDR, and MDR strains. Sensitivity and specificity of detection of mutations were 96% and 86% using MGIT resistance as a reference. Conclusions: Phenotypic methods for testing ethionamide are imperfectly correlated, and the isolates with MIC of 5 mg/L have the intermediate resistance. A significant proportion of resistant TB cases are susceptible and eligible for ethionamide treatment. Resistance could be explained using only analysis of loci ethA, PfabG1, and inhA for most isolates in the Moscow region. The promoter mutation PfabG1 c(-15)t predicts resistance to ethionamide with high specificity but low sensitivity.

13 October 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
AUAnastasia Ushtanit
Anastasia Ushtanit
YMYulia Mikhailova
Yulia Mikhailova
ALAlexandra Lyubimova
Alexandra Lyubimova
MMMarina Makarova
Marina Makarova
SSSvetlana Safonova
Svetlana Safonova
Danila ZimenkovDanila Zimenkov
Danila Zimenkov
Background: Linezolid, bedaquiline, and newer fluoroquinolones are currently placed as priority Group A drugs for the treatment of drug-resistant tuberculosis. The number of reported linezolid-resistant clinical strains is still low, and the correlation of molecular determinants with phenotype is not perfect. Methods: We determined the linezolid MICs for clinical isolates from the Moscow region and identified mutations in rplC and rrl genes. Results: All 16 linezolid-resistant isolates had previously reported mutations in the rplC or rrl loci, and 13 of them bore a RplC C154R substitution. Detection of this substitution in a heteroresistant state was not successful, probably, due to the more stable DNA secondary structure of the mutated fragment, which precludes its amplification in mixes with the wild-type DNA. Strains with an rplC mutation had higher linezolid MIC compared to isolates with rrl mutations. Conclusions: Linezolid resistance mostly emerged during treatment with the latest regimen. Three primary cases with linezolid resistance question the possible transmission of totally drug-resistant tuberculosis in the Moscow region, which demands further investigation.

15 March 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
AUAnastasia Ushtanit
Anastasia Ushtanit
YMYulia Mikhailova
Yulia Mikhailova
LKLudmila Krylova
Ludmila Krylova
DGDmitry Grigorash
Dmitry Grigorash
MMMarina Makarova
Marina Makarova
Danila ZimenkovDanila Zimenkov
Danila Zimenkov
The emergence of drug-resistant tuberculosis forced the development of new drugs and the screening of more effective or less toxic analogues. Mycolic acid biosynthesis is targeted by several antituberculosis drugs, isoniazid being one of the most important in tuberculosis therapy. Recently, perchlozone, acting on another step in the FAS-II cycle, was officially approved for tuberculosis treatment in the Russian Federation and was included in the Russian national clinical guidelines. Using the serial dilution method on 7H10 agar plates for perchlozone and a Sensititre MYCOTB microdilution plate, we analyzed the phenotypic properties of primary clinical isolates of M. tuberculosis and analyzed the molecular determinants of resistance to isoniazid, ethionamide, and perchlozone. We found a wide variation in the MIC of perchlozone from 2 to 64 mg/L, correlating with the overall resistance profile: the MIC was higher for MDR and pre-XDR isolates. The cross-resistance between ethionamide and perchlozone was driven by mutations in the ethA gene encoding monooxygenase responsible for the activation of both drugs. The presumably susceptible to perchlozone and wild-type strains had MICs ranging from 2 to 4 mg/L, and the breakpoint was estimated to be 4 or 8 mg/L. In conclusion, susceptibility to perchlozone is retained for a part of the MDR strains, as is susceptibility to ethionamide, providing the possibility of therapy for such cases based on phenotypic or molecular analysis.

Verified
Journal Article
Open access
PDF file
Danila ZimenkovDanila Zimenkov
Danila Zimenkov
YAYuliana Asenova Atanasova
Yuliana Asenova Atanasova
AUAnastasia Ushtanit
Anastasia Ushtanit
SYStanislava Yordanova
Stanislava Yordanova
ABAna Baykova
Ana Baykova
EBElizabeta Bachiyska
Elizabeta Bachiyska
We investigated the rise of nontuberculous mycobacteria (NTM) infections in Bulgaria, focusing on species identification and distribution from 2018 to 2022. Utilizing advanced diagnostic tools, including the Hain Mycobacterium CM/AS method, Myco-biochip assay, and whole-genome sequencing, the study identifies and characterizes a diverse range of Mycobacterium species from clinical samples. While M. avium, M. gordonae, M. fortuitum, and M. chelonae were dominating, a number of rare species were also found. They include such species as M. marseillense and M. celatum. Moreover, the noticeable prevalence of M. terrae complex species missed by conventional testing was observed. We identified a rare species, highly homologous to previously described strains from Japan; based on genome–genome distance data, we propose its reannotation as a new species. Further, a novel species was identified, which is significantly distinct from its closest neighbor, M. iranicum, with ANI = 87.18%. Based on the SeqCode procedure, we propose to name this new species Mycobacterium bulgaricum sp. nov. Dynamic changes in NTM species prevalence in Bulgaria observed from 2011 to 2022 highlight the emergence of new species and variations tied to environmental and demographic factors. This underscores the importance of accurate species identification and genotyping for understanding NTM epidemiology, informing public health strategies, and enhancing diagnostic accuracy and treatment protocols.

Verified
Journal Article
Open access
PDF file
Danila ZimenkovDanila Zimenkov
Danila Zimenkov
AUAnastasia Ushtanit
Anastasia Ushtanit
Infections caused by nontuberculous mycobacteria are becoming significant due to the increasing number of vulnerable individuals worldwide. Understanding the evolutionary relationships within the genus Mycobacterium is critical for improving species identification and, consequently, enhancing diagnosis, treatment, and epidemiological tracking. Pairwise comparisons of average nucleotide identity, genome–genome distance calculations, Mash values, multilocus sequence analyses, and average amino acid identities (AAIs) revealed that the AAI metric is the best to distinguish Mycobacterium from other genera of Mycobacteriales. Furthermore, genes encoding 16S and 23S rRNAs could also be used for the genus delineation: the previously established threshold of 94.5–95.0% of the rrs was confirmed, and the value for the rrl gene was estimated at 88.5–89.0%. The genus-delineating thresholds do not confirm the proposed splitting of the Mycobacterium into five genera, and the overall performance of conserved signatures used for splitting was not satisfactory. We estimated that Mycobacterium contains at least 402 distinct species, 246 of which were identified in clinical human specimens. The obtained tree and the corresponding list of species with proposed corrections to the names made from whole-genome sequences provide a reliable framework for the identification and taxonomic positioning of novel species within the genus.

Verified
Journal Article
Open access
PDF file
Danila ZimenkovDanila Zimenkov
Danila Zimenkov
VZViacheslav Zhuravlev
Viacheslav Zhuravlev
AUAnastasia Ushtanit
Anastasia Ushtanit
MFMarina Filippova
Marina Filippova
USUliana Semenova
Uliana Semenova
PYPeter Yablonsky
Peter Yablonsky
Infections caused by nontuberculous mycobacteria (NTM) are rising globally throughout the world. The number of species isolated from clinical samples is steadily growing, which demands the implementation of a robust diagnostic method with wide specificity. This study was carried out in in 2022–2024 in three clinical antituberculosis centers in the biggest cities of Russia: Moscow, Saint Petersburg, and Novosibirsk. We developed the DNA hybridization assay ‘Myco-biochip’ that allows the identification of 79 mycobacterial species and analyzed 3119 samples from 2221 patients. Sixty-eight mycobacterial species were identified in clinics, including the three novel species phylogenetically related to M. duvalii, M. lentiflavum, and M. talmoniae. The identification of a close relative of M. talmoniae adds to the existence of separate clade between M. terrae, M. triviale complexes and other slow-growing Mycobacteria, which supports the thesis against the splitting of Mycobacteria into five separate genera. Adding to the list of potentially pathogenic species, we identified M. adipatum and M. terramassiliense, which were previously described as natural habitats. The diversity of acid-fast bacilli identified in TB-suspected persons was not limited to the Mycobacteria genus and also includes species from genera Nocardia, Gordonia, Corynebacterium, Tsukamurella, and Rhodococcus of the order Mycobacteriales. The revealed bacterial diversity in patients with suspected NTM-diseases requires the implementation of relevant species identification assays as the first step in the laboratory diagnostic pipeline.